ARS Pharma Cuts H2 2026 Cash SG&A, R&D Spending Over 40% as Neffy Share Reaches 5%
Updated
Updated · Yahoo Finance · Aug 21
ARS Pharma Cuts H2 2026 Cash SG&A, R&D Spending Over 40% as Neffy Share Reaches 5%
1 articles · Updated · Yahoo Finance · Aug 21
Summary
$100 million to $110 million in cash SG&A and R&D spending is now projected for H2 2026, down more than 40% from the first half as new CEO Donn Casale tightens costs.
$95.1 million in Q2 operating expenses dwarfed $33.7 million in revenue, after broad consumer advertising failed to convert well for a prevention-based allergy market, pushing ARS toward narrower commercial targeting.
Neffy still showed traction: U.S. market share doubled to 5% from 2.5% a year earlier, reached 8% in covered sales territories, and drew more than 16,000 unique prescribers in the quarter.
The company said that lower spending should continue through 2027, while its phase IIb chronic spontaneous urticaria interim readout slipped from late 2026 to Q1 2027 because patients must log three flare episodes.